Oxford BioDynamics (OBD) is a health-care service company with a proprietary biomarker discovery platform, EpiSwitch, based on the latest advances in the mechanisms of gene expression, non-coding RNA and epigenetics. The technology allows: 1. Screening; early detection and monitoring of major diseases associated with aberrant gene expression, i.e. Cancer, neurodegenerative conditions, such as Alzheimer’s disease, and inflammatory conditions. 2. Early detection of aberrant expression in a very low copy number of abnormal cells, literally “finding a needle in a hay stack” at the early stage of the disease EpiSwitch способна определять 2 типа маркеров: Disease-related biomarkers (diagnostic biomarker and prognostic biomarker) и Drug-related biomarkers.